HCL-TECHNOLOGIES
Three winners of HCL Grant 2017 across categories of Environment, Health and Education were today announced at a ceremony held at HCL Technologies Hub, Noida. Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs , presided over the ceremony as the Chief Guest and felicitated the winners. Each winning NGO receives a Grant of up to INR 5 crores.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170221006559/en/
At the occasion, Shri Arun Jaitley also released a compendium titled “The Fifth Estate - NGOs transforming Rural India in Environment, Health and Education ,” which is a compilation of all the finalists of the second edition of HCL Grant.
Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs, congratulated the winners of HCL Grant 2017 and appreciated the work of HCL and the jury.
Addressing the gathering he said , “I must compliment HCL for going into the larger society, creating an independent jury, looking at areas which need support and getting the jury to select the best so that the winners can be role models for others.”
Malcolm Gladwell , an eminent author and speaker, attended the ceremony as a Special Guest and addressed the gathering comprising Board members, senior leadership and other distinguished guests from various walks of life.
The winning NGOs across three categories are:
- Environment - Foundation of Ecological Security (Gujarat)
- Health - Child in Need Institute (CINI) (West Bengal)
- Education - MelJol (Maharashtra)
Ms. Robin Abrams, Chairperson of Jury, HCL Grant, said, “HCL Grant is so much more than the fund itself. The mark of the strategic value of any grant is leverage. From the focus on governance and sustainability, sharing of best practices and how corporates and their employees can engage with NGOs – HCL Grant delivers on strategic value for the NGOs of India and for India’s Fifth Estate. It is exciting to be a part of this kind of leverage.”
HCL Grant, a CSR commitment by HCL through HCL Foundation, envisions to contribute to rural development by strengthening NGOs through deep institutional involvement and commitment. The Grant stands testimony to the fact that only strong governance structures management capabilities and reliable impact measurement systems within NGOs can help them take up and sustain high impact, complex and social transformational projects.
The winning NGOs have been selected by an eminent jury panel. Members of the panel are Ms. Robin Abrams – Former President of Palm Computing, and the longest serving Board member of HCL Technologies; Dr. Isher Judge Ahluwalia - Leading Economist and Chairperson, Board of Governors, the Indian Council for Research on International Economic Relations; Ms. Pallavi Shroff - Eminent Legal Counsel, Shardul Amarchand Mangaldas & Co.; Mr. B.S. Baswan - Former Director, Indian Institute of Public Administration; Mr. Richard Lariviere - President, Field Museum, Chicago and Former President of the University of Oregon; Dr. John E. Kelly – Senior Vice President, Cognitive Solutions and Research, IBM Corporation; and Mr. Shiv Nadar – Founder & Chairman, HCL and Shiv Nadar Foundation.
For more information please visit www.hcltech.com/HCL-Grant .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170221006559/en/
Contact:
HCL Technologies
Ajay Davessar, +91 120 43828280
VP & Global
Head - Corporate Communications
Ajay.davessar@hcl.com
Link:
Social Media:
https://www.facebook.com/https://www.facebook.com/HCLTechnologies
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
